Document Detail


Helicobacter pylori treatment in the era of increasing antibiotic resistance.
MedLine Citation:
PMID:  20525969     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
With few exceptions, the most commonly recommended triple Helicobacter pylori regimen (proton pump inhibitor (PPI), amoxicillin and clarithromycin) now provides unacceptably low treatment success. A review of worldwide results suggests that successful eradication using a triple regimen is not consistently observed in any population. Clinicians should use 'only use what works locally' and ignore consensus statements and society guidelines if they are not consistent with local results. Clinical trials should be result based, with the goal of identifying regimens with >90-95% success. New treatments should be only be compared with the currently locally effective treatment (>90%) or a historical untreated control (which has been shown to reliably yield 0% eradication); trials using placebos or treatments known to be inferior are with rare exceptions unethical. If a highly effective regimen is not available locally, we recommend trying a 14 day concomitant quadruple treatment regimen containing a PPI, amoxicillin, clarithromycin and a nitroimidazole; 10 day sequential treatment (PPI plus amoxicillin for 5 days followed by a PPI, clarithromycin and a nitroimidazole for 5 days); or 14 day bismuth-containing quadruple treatments. Treatments needing further evaluation include those containing furazolidone or nitazoxanide, hybrids of sequential-concomitant therapies and amoxicillin-PPI dual therapy with PPI doses such that they maintain intragastric pH >6.
Authors:
David Y Graham; Lori Fischbach
Related Documents :
3726009 - Psychological correlates of gastric and duodenal ulcer disease.
25133079 - A total motion release warm-up improves dominant arm shoulder internal and external rot...
14499769 - Step-down from multiple- to single-dose proton pump inhibitors (ppis): a prospective st...
23276629 - Management of symptoms of restless legs syndrome with use of a traction straight leg ra...
1912429 - A double-blind study of misoprostol (sc-29333) in the healing of duodenal ulcer.
9222709 - Pantoprazole-based dual and triple therapy for the eradication of helicobacter pylori i...
16480819 - Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depress...
22985519 - Hyper-phosphorylation of gsk-3β: possible roles in chlorpyrifos-induced behavioral alte...
19238389 - A method for calcium quantification by means of ct coronary angiography using 64-multid...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2010-06-04
Journal Detail:
Title:  Gut     Volume:  59     ISSN:  1468-3288     ISO Abbreviation:  Gut     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-11-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985108R     Medline TA:  Gut     Country:  England    
Other Details:
Languages:  eng     Pagination:  1143-53     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas 77030, USA. dgraham@bcm.tmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Bacterial Agents / therapeutic use*
Drug Resistance, Bacterial
Drug Therapy, Combination
Helicobacter Infections / drug therapy*
Helicobacter pylori / drug effects*
Humans
Practice Guidelines as Topic
Treatment Failure
Treatment Outcome
Grant Support
ID/Acronym/Agency:
DK56338/DK/NIDDK NIH HHS; R01 CA116845/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Managing HBV in patients with impaired immunity.
Next Document:  Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation i...